{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0"},{"groupId":"OG001","value":"58.7"},{"groupId":"OG002","value":"61.5"},{"groupId":"OG003","value":"62.3"},{"groupId":"OG004","value":"60.0"},{"groupId":"OG005","value":"62.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"523"},{"groupId":"OG001","value":"482"},{"groupId":"OG002","value":"444"},{"groupId":"OG003","value":"414"},{"groupId":"OG004","value":"390"},{"groupId":"OG005","value":"370"}],"units":"Participants"}],"description":"Quality of life is measured using the sub-scale for Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F). The assessment was originally developed for chronic illnesses and is now widely used for patients with rheumatoid arthritis.\n\nFACIT-F is a 13-item questionnaire. Participants score each item on a 5-point scale: 0 (Not at all) to 4 (Very much), for a highest possible score of 52. The responses are transformed into a FACIT-F score, where a higher score reflects an improvement. The percentage of participants with at least a 5-point improvement from baseline in the Facit-F score is shown at categorical time points.","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"NUMBER","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Percentage of Participants With at Least a 5-point Improvement From Baseline in Quality of Life Measure for Fatigue Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}